Delcath Seeks FDA Approval for Chemo Drug and Device

Delcath Systems may be less than six months away from being able to sell its liver chemotherapy system in the United States — which could be a turning point for a company that has been in the development stage for 24 years. The application covers both the Hepatic Chemostat therapy device and the drug — melphalan hydrochloride.
The Business Review